Rare disease leadership Sobi is a global biopharma leader focusing on rare diseases with strong hematology and immunology franchises, providing a solid platform for partnering on specialized therapies and expanded indications.

Strategic collaborations Recent partnerships, including the Innate Pharma licensing deal for lacutamab in T-cell lymphoma, indicate openness to license-and-collaborate models that unlock new revenue streams and reduce time-to-market risk.

Growth momentum 2025 revenue reached approximately SEK 28 billion with hematology driving the majority, signaling healthy demand and potential cross-sell opportunities across related rare-disease segments and companion diagnostics.

Executive transition Upcoming CEO transition in early 2027 suggests a window for strategic alignment, advisory engagements, and targeted partnerships that align with the new leadership’s priorities and vision.

Global reach Sobi operates across Europe, North America, the Middle East, Asia and Australia, presenting broad geographic expansion opportunities for clinical development services, regulatory support, and market-access collaborations.